Eli Lilly has announced an additional investment of $4.5 billion in its Indiana production base, alongside the activation of its first new facility dedicated exclusively to gene medicine manufacturing. This brings Eli Lilly's total capital commitments in the state since 2020 to over $21 billion.
The additional investment will be allocated to two key facilities in the Lebanon area: one is an active pharmaceutical ingredient (API) production base scheduled to commence operations in 2027, which, upon completion, will become the largest API production facility in U.S. history; the other is the Lilly Lebanon Advanced Therapies gene medicine factory, which officially began operations today. This is Eli Lilly's first factory focused on both clinical and commercial production of gene medicines.
The company stated that the latest investment will deploy next-generation manufacturing technologies and processes to expand production of several core drugs. These include the weight-loss medications Zepbound and Mounjaro, the newly approved oral weight-loss drug Foundayo, and the investigational triple-hormone receptor agonist retatrutide. Eli Lilly's Chairman and CEO David Ricks emphasized, "When our Lebanon API site opens in 2027, it will be the largest API manufacturing facility in U.S. history, a commitment we are choosing to build in our home state."
Indiana Governor Mike Braun stated that this expansion reflects the deep collaborative relationship between Eli Lilly and Indiana, further solidifying the state's leading position in life sciences and advanced manufacturing. According to a report to be released next week by Indiana University's Kelley School of Business, Eli Lilly contributes to 70% of Indiana's pharmaceutical industry GDP, and each Eli Lilly job supports over two additional jobs statewide.
